Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
APPROVAL AND DISCONTINUATION OF SYSTEMIC ANTIBACTERIAL DRUGS IN THE US(JANUARY1938- DECEMBER2018)
- At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
- Type: Poster
- By: ALQAHTANI, Saad (Jazan University, Clinical Pharmacy, Saudi Arabia)
- Co-author(s): Saad Saeed Alqahtani: Clinical Pharmacy Department, Jazan University, JAZAN, Saudi Arabia;Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, JAZAN, Saudi Arabia
Enrique Seoane-Vazquez: School of Pharmacy, Economic Science Institute, Chapman University, Irvine, CA, United States
Rosa Rodriguez-Monguio: Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, San Francisco, CA, United States
Abdulrhman Alsayri: Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
BackgroundDespite the clinical and economic importance of systemic antibacterial drugs, only a few studies have assessed short-term approvals and discontinuations of systemic antibacterials in the US.
MethodsData were extracted from publicly available data on the FDA website: Drugs@FDA. The dates of approval and market status were confirmed using.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019